Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Current Assets for 9 consecutive years, with $882.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 1.58% to $882.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $882.6 million, a 1.58% increase, with the full-year FY2024 number at $864.4 million, down 18.77% from a year prior.
  • Current Assets was $882.6 million for Q3 2025 at Denali Therapeutics, down from $934.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.4 billion in Q1 2021 to a low of $864.4 million in Q4 2024.
  • A 5-year average of $1.1 billion and a median of $1.1 billion in 2021 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 139.85% in 2021; the steepest drop was 40.01% in 2021.
  • Denali Therapeutics' Current Assets stood at $897.2 million in 2021, then skyrocketed by 52.95% to $1.4 billion in 2022, then dropped by 22.46% to $1.1 billion in 2023, then decreased by 18.77% to $864.4 million in 2024, then grew by 2.1% to $882.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Current Assets are $882.6 million (Q3 2025), $934.7 million (Q2 2025), and $878.6 million (Q1 2025).